20 results on '"Bertilsson L"'
Search Results
2. Quinidine inhibition of debrisoquine S( )-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes
- Author
-
Bertilsson, L, Meese, C O, Yue, Q Y, Dahl, M L, Ingelman-Sundberg, M, Johansson, I, Säwe, J, and Eichelbaum, M
- Abstract
Pronounced differences in the CYP2D6 gene between Chinese and Caucasians have previously been described. There was a low frequency of detrimental mutations in the Chinese CYP2D6 gene causing the poor metabolizer (PM) phenotype. In contrast to Caucasians where the Xba 144 kb allele is almost always associated with the PM phenotype, Chinese with the 4444 kb RFLP pattern are extensive metabolizers (EM). In order to evaluate whether the debrisoquine hydroxylation seen in subjects with this haplotype is catalysed by a functionally similar enzyme to CYP2D6 or is catalysed by another type of P450 isozyme, product selectivity of the 4-hydroxylation was studied in 27 Chinese. The inhibition of CYP2D6 by quinidine was also investigated.
- Published
- 1993
3. Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden.
- Author
-
Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, and Ingelman-Sundberg M
- Subjects
- Adult, Aryl Hydrocarbon Hydroxylases genetics, Cytochrome P-450 CYP2C19, Ethiopia ethnology, Female, Genotype, Humans, Male, Middle Aged, Mixed Function Oxygenases genetics, Phenotype, Substrate Specificity, Sweden, Black People genetics, Cytochrome P-450 CYP2D6 genetics, Environment, White People genetics
- Abstract
Black Africans show lower rates of CYP2D6- and CYP2C19-dependent drug metabolism compared to Caucasians of the same apparent genotype. To determine if environmental factors are responsible for this difference, the genotypes and phenotypes of CYP2D6 and CYP2C19 among Ethiopians living in Sweden (n = 70) were assessed and compared to our previously published data from Ethiopians living in Ethiopia (n = 114) and Swedish Caucasians (n = 134). There was no significant difference in CYP2C19 genotype or phenotype as assessed by mephenytoin between Ethiopians in Sweden or in Ethiopia. However, Swedes were significantly more rapid for CYP2C19 activity than both Ethiopian groups (P < 0.01). A comparison of the debrisoquine MR among individuals of the same CYP2D6 genotype revealed that Swedes exhibited the highest rate of debrisoquine metabolism, followed by Ethiopians in Sweden and Ethiopians in Ethiopia. The difference between the Ethiopian groups was significant (P < 0.02 using a univariate test ANOVA) and amounted to approximately 50% of the magnitude of the MR difference between Swedes and Ethiopians in Ethiopia. It is tempting to speculate that inhibitory dietary factors may explain the differences seen between the two Ethiopian groups and that these components in the past might have contributed to dietary stress-mediated selection of duplicated and multiduplicated active CYP2D6 genes, as frequently seen in Ethiopians. In conclusion, the results indicate a significant influence of environmental factors as an explanation for the difference in capacity for CYP2D6, but not CYP2C19 metabolism between Caucasians and Black Africans. Additional factors remain to be elucidated to fully explain the interethnic differences in CYP2D6 activity.
- Published
- 2002
- Full Text
- View/download PDF
4. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity.
- Author
-
Wennerholm A, Johansson I, Hidestrand M, Bertilsson L, Gustafsson LL, and Ingelman-Sundberg M
- Subjects
- Animals, COS Cells, Catalysis, Cytochrome P-450 CYP2D6 metabolism, DNA Primers, Humans, Mutagenesis, Site-Directed, Tanzania, Alleles, Black People genetics, Cytochrome P-450 CYP2D6 genetics
- Abstract
Debrisoquine metabolism among Tanzanians has been found to be slower than expected from the CYP2D6 genotype. In order to evaluate any genetic explanation, the coding sequence and intron-exon boundaries of the CYP2D6 gene from three Black Tanzanian volunteers with a CYP2D6*1/*1 or CYP2D6*2/*2 genotype and debrisoquine metabolic ratios (MRs) > 1 were fully sequenced to screen for new mutations. Two functional mutations, G1747 to A (causing V136I) and G3271 to A (causing V338M), were identified in the CYP2D6*2/*2 sample. Thirty-six subjects (34%) out of a total 106 subjects were heterozygous and three subjects (3%) were homozygous for the allele, yielding an allele frequency of 20%. The CYP2D6*29 allele, having also the mutations of the CYP2D6*2 allele, was subsequently expressed in yeast and mammalian COS-1 cells. No differences were seen with respect to the affinity (Km) or maximal velocity (Vmax) of the CYP2D6 substrate bufuralol between the wild-type and mutant when expression was carried out in yeast cells. By contrast, the 1'-hydroxybufuralol catalytic activity of the mutant expressed in COS-1 cells was only 26% of the wild-type (P < 0.01; Mann-Whitney U-test) and its debrisoquine hydroxylation activity was 63% of that of CYP2D6.1. The single mutants V136I and V338M had reduced capacity for bufuralol hydroxylation, but the effect was even stronger when both mutations were present together as in CYP2D6.29. Analysis of the distribution of CYP2D6*29 in subjects phenotyped for debrisoquine revealed that this allele significantly causes a reduction in the rate of debrisoquine hydroxylation in vivo. The results indicate the common existence in Tanzanians of a variant CYP2D6 form with different substrate specificity as compared to the wild-type form of the enzyme causing reduced capacity for debrisoquine metabolism.
- Published
- 2001
- Full Text
- View/download PDF
5. Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype.
- Author
-
Wennerholm A, Johansson I, Massele AY, Lande M, Alm C, Aden-Abdi Y, Dahl ML, Ingelman-Sundberg M, Bertilsson L, and Gustafsson LL
- Subjects
- Base Sequence, DNA Primers, Ethnicity, Female, Genotype, Humans, Male, Mutation, Phenotype, Tanzania, Black People genetics, Cytochrome P-450 CYP2D6 genetics, Debrisoquin pharmacokinetics
- Abstract
The cytochrome P450 2D6 (CYP2D6) genotypes and phenotypes of 106 unrelated, healthy black Tanzanians of Bantu origin were investigated. The results revealed a population with a generally decreased capacity to metabolize the CYP2D6 substrate debrisoquine with 59% of the Tanzanian extensive metabolisers having debrisoquine metabolic ratios (MRs) > 1 versus 20% in Caucasians. This decrease in metabolic capacity was not fully explained by the partially or fully detrimental CYP2D6 gene mutations analysed for in this study. As many as 7% poor metabolizers of debrisoquine were identified but none was homozygous for defective CYP2D6 alleles. The majority among the group of poor metabolizers had relatively low metabolic ratios. The mutational profile indicated a closer association of the Tanzanian CYP2D locus to that of Zimbabweans rather than to that of Ethiopians. The defective alleles CYP2D6*3, *4, *5 and *6 were found at low frequencies (0%, 1%, 6%, 0%, respectively), whereas the CYP2D6*17 allele causing an enzyme with altered specificity was common (allele frequency = 17%). It is concluded that the CYP2D6 genotype in the Tanzanian Bantu population is different from that of other African populations examined to date and that further studies are required to explain the generally lower capacity to metabolize CYP2D6 substrates.
- Published
- 1999
6. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.
- Author
-
Dalén P, Dahl ML, Eichelbaum M, Bertilsson L, and Wilkinson GR
- Subjects
- Adolescent, Adult, Area Under Curve, Female, Genotype, Humans, Male, Cytochrome P-450 CYP2D6 genetics, Debrisoquin pharmacokinetics, White People genetics
- Abstract
Debrisoquine is a major prototypic in-vivo probe used to assess polymorphic CYP2D6 activity in humans, based on the 0-8 h urinary excretion of unchanged drug and its 4-hydroxy metabolite (the so-called metabolic ratio). The primary purpose of the study was to investigate further the relationship between genotype and phenotype by determining the overall disposition characteristics of the drug in selected groups of healthy Swedish Caucasian individuals. Debrisoquine (20 mg) was orally administered to five poor metabolizers with no functional CYP2D6 gene, five heterozygous extensive metabolizers, five homozygous extensive metabolizers, five ultrarapid metabolizers with duplicated/triplicated CYP2D6*2 genes and one individual with 13 copies of CYP2D6*2. Peak plasma levels of debrisoquine and 4-hydroxydebrisoquine were attained within 2-4 h and then declined in a multi-exponential fashion over 96 h. However, the post 8-h period of the elimination process was characterized by irregular fluctuations that prevented formal pharmacokinetic analysis. Nevertheless, marked differences were apparent in the compounds' plasma level-time profiles between the CYP2D6 genotypes. For example, in the case of debrisoquine, the mean ratio of the AUC(0-8) values was 22:22:7:6:1, corresponding to 0, 1, 2, 3/4 and 13 genes and, for 4-hydroxydebrisoquine, the respective values were 1:7:19:28:17. The 0-96 h urinary recovery of debrisoquine differed 100-fold between the genotypes, being essentially complete in poor metabolizers and zero in the individual with 13 CYP2D6*2 genes. 4-hydroxydebrisoquine excretion increased according to the number of functional CYP2D6 genes. A highly significant correlation (r(s) = 0.95, P < 0.001) was observed between the plasma AUC(0-8) ratio for debrisoquine to 4-hydroxydebrisoquine and the 0-8 h urinary metabolic ratio. This study demonstrates that the number of functional CYP2D6 alleles is critically important in the plasma concentration-time curves of debrisoquine and its CYP2D6-mediated 4-hydroxy metabolite. Concentration-related pharmacologic effects would be expected to be similarly affected by gene dosage and it is likely that the same situation also applies to other drugs whose elimination is importantly determined by this enzyme; for example, many antidepressants and neuroleptics, antiarrhythmic agents, beta-adrenoceptor antagonists and opiates.
- Published
- 1999
- Full Text
- View/download PDF
7. Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine.
- Author
-
Bernal ML, Sinues B, Johansson I, McLellan RA, Wennerholm A, Dahl ML, Ingelman-Sundberg M, and Bertilsson L
- Subjects
- Adult, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Pharmacogenetics, Phenotype, Spain, Cytochrome P-450 CYP2D6 genetics, Cytochrome P-450 CYP2D6 metabolism, Debrisoquin metabolism, Gene Duplication
- Published
- 1999
8. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands.
- Author
-
Kaneko A, Lum JK, Yaviong L, Takahashi N, Ishizaki T, Bertilsson L, Kobayakawa T, and Björkman A
- Subjects
- Antimalarials metabolism, Child, Cytochrome P-450 CYP2C19, Female, Gene Frequency, Genetic Variation, Genotype, Humans, Male, Pacific Islands, Pharmacogenetics, Proguanil metabolism, Selection, Genetic, Vanuatu, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System genetics, Cytochrome P-450 Enzyme System metabolism, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism, Mutation
- Abstract
Cytochrome P450 (CYP) 2C19 is polymorphic with poor metabolizers representing 3-6% of Europeans and Africans, and 13-23% of Asians. Greater than 99% of the poor metabolizer alleles in Asian populations are defined by two single base pair mutations (CYP2C19*2 and CYP2C19*3). We have recently reported an unprecedentedly high prevalence (71%) of CYP2C19-related poor metabolizer genotype individuals and poor metabolism of proguanil on two malarious islands of Vanuatu in eastern Melanesia. To elucidate this further, a total of 5538 individuals from 24 populations on 16 different islands of Vanuatu were genotyped. Of these, 61% had a poor metabolizer genotype (*2/*2, *2/*3 or *3/*3) with substantial variation among the populations (38-79%). The overall frequencies of CYP2C19*1 (wild-type), CYP2C19*2, and CYP2C19*3 were 0.223, 0.633, and 0.144, respectively. A significant linear correlation was observed between heterozygosity and South latitude (r = 0.552, P < 0.05). The genotype frequencies of 21 of the 24 populations were consistent with Hardy-Weinberg expectations (P > 0.05). Comparisons of genetic, linguistic and geographical patterns among populations suggest that short range gene flow is largely responsible for the current distribution of CYP2C19 alleles in Vanuatu. Taken together with previous studies of nuclear genetic loci of Pacific island populations, these data predict that the poor metabolizer genotype is common throughout Polynesia and Micronesia and may be even more prevalent in western Melanesia than in Vanuatu. This suggests that the majority of Pacific Islanders metabolize a wide variety of clinically important drugs to a significantly lower degree than the average European.
- Published
- 1999
9. Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping.
- Author
-
Svensson JO and Bertilsson L
- Subjects
- Cytochrome P-450 CYP2D6 genetics, Humans, Phenotype, Spectrometry, Fluorescence, Chromatography, High Pressure Liquid methods, Cytochrome P-450 CYP2D6 metabolism, Debrisoquin analogs & derivatives, Debrisoquin urine
- Published
- 1999
10. An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin.
- Author
-
Tybring G, Nordin J, Bergman T, and Bertilsson L
- Subjects
- Chromatography, High Pressure Liquid, Gas Chromatography-Mass Spectrometry, Humans, Mephenytoin urine, Phenotype, Cysteine metabolism, Mephenytoin pharmacokinetics
- Abstract
A conjugate of S-mephenytoin excreted in urine of extensive but not of poor metabolizers of S-mephenytoin has previously been reported. This conjugate, which is easily hydrolysed back to S-mephenytoin, has now been isolated and identified in urine from one extensive metabolizer after a single dose of 100 mg racemic mephenytoin. High performance liquid chromatography purification, followed by gas chromatographic, mass spectrometric and amino acid analyses showed that the isolated compound is a cysteine conjugate of S-mephenytoin. The significant mass spectrometric ions have been confirmed in three additional extensive metabolizers of S-mephenytoin, but were not detectable in urine from three poor metabolizer subjects. The exact structure of the conjugate is unknown, but we suggest that an S-N bond between cysteine and S-mephenytoin is formed via an oxidative radical mechanism catalyzed by CYP2C19.
- Published
- 1997
- Full Text
- View/download PDF
11. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population.
- Author
-
Roh HK, Dahl ML, Tybring G, Yamada H, Cha YN, and Bertilsson L
- Subjects
- Administration, Oral, Adult, Alleles, Cytochrome P-450 CYP2C19, Cytochrome P-450 Enzyme System metabolism, Female, Genotype, Humans, Korea, Male, Mixed Function Oxygenases metabolism, Omeprazole administration & dosage, Omeprazole pharmacokinetics, Phenotype, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System genetics, Gene Frequency, Mixed Function Oxygenases genetics, Omeprazole metabolism
- Abstract
Omeprazole (20 mg orally) was given to 103 healthy Korean subjects and blood was taken 3 h after administration. The plasma concentration ratio of omeprazole and hydroxyomeprazole, used as an index of CYP2C19 activity, was bimodally distributed. Thirteen subjects (12.6%) were identified as poor metabolizers (PMs) with an omeprazole hydroxylation ratio of 6.95 or higher. Among the 206 CYP2C19 alleles, CYP2C19*2 and CYP2C19*3 were found in 43 alleles (21%) and 24 alleles (12%), respectively. Twelve subjects (12%) carried two defect alleles (*2/*2, *2/*3 or *3/*3), 43 subjects (42%) were heterozygous for a mutated (*2 or *3) and a wild type (*1) allele, and the remaining 48 subjects (47%) were homozygous for the wild type allele. The distributions of the metabolic ratio between these three genotype groups were significantly different (Kruskal-Wallis test: p < 0.0001). The genotypes of 19 additional Korean PMs has been identified in a previous mephenytoin study. From a total of 32 PMs, 31 were genotypically PMs by analysis of the CYP2C19*2 and *3 alleles and only one PM subject was found to be heterozygous for the *1 and *2 alleles. At present it cannot be judged whether this subject has a defective allele with a so-far unidentified mutation or a true wild type allele. We thus confirm a high incidence (12.6%) of PMs of omeprazole in Koreans and of the 32 Korean PMs 97% could be identified by the genotype analysis.
- Published
- 1996
- Full Text
- View/download PDF
12. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
- Author
-
Persson I, Aklillu E, Rodrigues F, Bertilsson L, and Ingelman-Sundberg M
- Subjects
- Alleles, Cytochrome P-450 CYP2C19, Cytochrome P-450 Enzyme System metabolism, Ethiopia, Female, Gene Frequency, Genotype, Humans, Male, Mixed Function Oxygenases metabolism, Phenotype, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System genetics, Mephenytoin metabolism, Mixed Function Oxygenases genetics, Polymorphism, Genetic
- Abstract
The polymorphic metabolism of S-mephenytoin and the distribution of two known deleterious mutant CYP2C19 alleles was determined among 114 healthy unrelated black Ethiopians. Six subjects (5.2%) were poor metabolizers (PMs) of S-mephenytoin. The frequencies of the defective CYP2C19*2 (CYP2C19m1) and CYP2C19*3 (CYP2C19m2) alleles were 0.14 and 0.02, respectively. Three of the PMs were homozygous for the CYP2C19*2 allele and the remaining three PMs were heterozygous for both the CYP2C19*2 and CYP2C19*3 mutant alleles. It is concluded that the frequency of PMs for S-mephenytoin is similar in Ethiopians, Zimbabweans and Caucasians and that the CYP2C19*3 allele, for the first time identified in a black population, together with the CYP2C19*2 allele account for all of the defective CYP2C19 alleles among the Ethiopian PMs.
- Published
- 1996
- Full Text
- View/download PDF
13. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population.
- Author
-
Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, and Bertilsson L
- Subjects
- Adult, Cytochrome P-450 CYP2D6 classification, Female, Gene Frequency, Genotype, Humans, Korea, Male, Phenotype, Point Mutation, Asian People genetics, Cytochrome P-450 CYP2D6 genetics, Debrisoquin metabolism, Mephenytoin metabolism, Polymorphism, Genetic
- Abstract
One hundred and fifty-two healthy Korean volunteers were phenotyped with debrisoquine and mephenytoin and genotyped with respect to CYP2D6. The debrisoquine metabolic ratio (MR) varied between 0.09 and 6.3, and all subjects were thus classified as extensive metabolizers of debrisoquine. Polymerase chain reaction (PCR)-based amplification of genomic DNA with primers specific for the C188-->T mutation present in exon 1 of the CYP2D6*10B allele was performed and revealed an allele frequency of 0.51 in this Korean population. Forty-three subjects (28%) were homozygous for CYP2D6*10B, 69 subjects (45%) were heterozygous for this allele, while in 40 subjects (26%) no exon 1 mutation could be found. All subjects except one homozygous for the wild type allele had MRs below 0.75 whereas the MR was higher than 0.99 in all subjects homozygous for the CYP2D6*10B allele. The MRs in the three genotype groups were significantly different (p < 0.0001; Kruskal-Wallis test). Eco RI RFLP analysis of DNA from six subjects with debrisoquine MRs < or = 0.11 revealed that only one (MR 0.09) carried a duplicated CYP2D6*Z-gene (CYP2D6*2X2) as indicated by the Eco RI 12.1 kb haplotype. It is concluded that, as shown earlier for Chinese and Japanese populations, the CYP2D6*10B-allele containing the C188-->T mutation is the major cause of diminished CYP2D6 activity in Koreans. In this Korean population, the MR of debrisoquine was shifted towards higher values (lower CYP2D6 activity) compared with Caucasian populations but the shift appeared to be less pronounced than earlier shown for Chinese. Twenty-four subjects (16%) were poor metabolizers of S-mephenytoin as indicated by the S/R mephenytoin ratio of about 1. Twenty-three of these were genotyped with respect to the defect CYP2C19-alleles CYP2C19*2 and CYP2C19*3. Of the 46 poor metabolizer alleles, 32 (70%) were CYP2C19*2 and the remaining 14 (30%) were CYP2C19*3. Thus, the defect CYP2C19*2 and CYP2C19*3-alleles explained 100% of the 23 Korean poor metabolizers of S-mephenytoin.
- Published
- 1996
- Full Text
- View/download PDF
14. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
- Author
-
Chang M, Dahl ML, Tybring G, Götharson E, and Bertilsson L
- Subjects
- 2-Pyridinylmethylsulfinylbenzimidazoles, Adult, Alleles, Cytochrome P-450 CYP2C19, Female, Genotype, Humans, Hydroxylation, Male, Middle Aged, Molecular Probes, Omeprazole administration & dosage, Omeprazole analogs & derivatives, Omeprazole pharmacokinetics, Pharmacogenetics, Phenotype, Sweden, White People genetics, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System genetics, Cytochrome P-450 Enzyme System metabolism, Mephenytoin metabolism, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism, Omeprazole metabolism
- Abstract
A single oral dose of omeprazole (20 mg) was given orally to 160 healthy Caucasian Swedish subjects and tested as a probe for CYP2C19. The study was nonrandomized and included seven subjects previously classified as poor metabolizers (PM) of S-mephenytoin. The ratio between the plasma concentrations of omeprazole and hydroxyomeprazole (metabolic ratio; MR) was determined by HPLC in a blood sample drawn 3 h after drug intake. In 17 subjects the test was repeated and the MRs of omeprazole on the two occasions were correlated (rs = 0.85; p < 0.0001). There was a significant correlation between the MR of omeprazole and the S/R mephenytoin ratio among 141 subjects, in whom both ratios were determined (rs = 0.63, p < 0.001). All seven PMs of S-mephenytoin had higher MRs of omeprazole (7.1-23.8) than extensive metabolizers (EM) (0.1-4.9). All 160 subjects and another 15 Caucasian Swedish PMs previously phenotyped with mephenytoin were analysed with respect to the presence of the CYP2C19m1 allele by PCR amplification of the intron 4/exon 5 junction followed by Sma I digestion. EMs heterozygous for the CYP2C19m1 gene had MRs of omeprazole and S/R ratios of mephenytoin that were higher than those of subjects who were homozygous for the wild-type allele (p = 0.0001). Nineteen of the 22 PMs were homozygous for the CYP2C19m1 gene. Three were heterozygous for this allele. Thus, 41 of the 44 alleles (93%) of PMs were defective CYP2C19m1. One of the remaining three PM alleles was subsequently found to contain the CYP2C19m2 mutation, which has earlier been shown to be associated with the PM phenotype in Oriental populations. In conclusion, the phenotype determined by omeprazole correlated with that of mephenytoin, and was in good agreement with the genotype.
- Published
- 1995
- Full Text
- View/download PDF
15. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
- Author
-
Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, and Bertilsson L
- Subjects
- Adult, Alleles, China ethnology, Cytochrome P-450 CYP2D6, Cytochrome P-450 Enzyme System metabolism, Female, Genotype, Humans, Hydroxylation, Japan ethnology, Korea ethnology, Male, Middle Aged, Mixed Function Oxygenases metabolism, Pilot Projects, Sweden, Cytochrome P-450 Enzyme System genetics, Debrisoquin metabolism, Mixed Function Oxygenases genetics
- Abstract
The CYP2D6 genotype and the debrisoquine and mephenytoin hydroxylation phenotypes were studied in 63 Oriental subjects including 21 Chinese, 21 Japanese and 21 Koreans. All subjects were extensive metabolizers of debrisoquine. The incidence of the S-mephenytoin poor metabolizer phenotype was 14% in the Chinese, 24% in the Japanese and 24% in the Korean population, respectively, which is similar to previous reports. The CYP2D6 genotype was analysed by Xba I and Eco RI RFLP, and by allele-specific PCR analysis for the presence of several allelic variants of the CYP2D locus. No CYP2D6A or CYP2D6B alleles, two of the most common defect alleles among Caucasians, were found among the Oriental subjects. The frequency of the CYP2D6D allele was similar to that in Caucasian populations and consistent with the low incidence of the poor metabolizer phenotype in all three Oriental populations. The CYP2D6L2-allele with duplication of an active CYP2D6L gene was identified in one Korean and one Chinese allele in association with high CYP2D6 activity. The CYP2D6Ch alleles CYP2D6Ch1 and Ch2, identified by RFLP and PCR for the -1338C-->T and 188C-->T mutations, were the most frequent allelic variants in all three populations studied, and were related to a decreased CYP2D6 activity as previously shown in Chinese. In conclusion, the present pilot study revealed major similarities in the polymorphic CYP2D locus between Korean, Japanese and Chinese populations.
- Published
- 1995
- Full Text
- View/download PDF
16. Codeine metabolism in three Oriental populations: a pilot study in Chinese, Japanese and Koreans.
- Author
-
Yue QY, Svensson JO, Säwe J, and Bertilsson L
- Subjects
- Adult, China ethnology, Cytochrome P-450 CYP2D6, Cytochrome P-450 CYP3A, Cytochrome P-450 Enzyme System genetics, Cytochrome P-450 Enzyme System metabolism, Female, Glucuronosyltransferase genetics, Glucuronosyltransferase metabolism, Humans, Japan ethnology, Korea ethnology, Male, Methylation, Middle Aged, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism, Pilot Projects, Sweden, Codeine metabolism
- Published
- 1995
- Full Text
- View/download PDF
17. Genetically variable metabolism of antidepressants and neuroleptic drugs in man.
- Author
-
Dahl ML and Bertilsson L
- Subjects
- Antidepressive Agents, Tricyclic metabolism, China, Cytochrome P-450 Enzyme System metabolism, Debrisoquin metabolism, Female, Humans, Hydroxylation, Liver metabolism, Male, Mephenytoin metabolism, Sweden, Antidepressive Agents metabolism, Antipsychotic Agents metabolism, Polymorphism, Genetic
- Published
- 1993
- Full Text
- View/download PDF
18. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.
- Author
-
Ingelman-Sundberg M, Johansson I, Persson I, Yue QY, Dahl ML, Bertilsson L, and Sjöqvist F
- Subjects
- Cytochrome P-450 CYP1A1, Cytochrome P-450 CYP2D6, Cytochrome P-450 Enzyme System metabolism, DNA Mutational Analysis, Humans, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism, Oxidoreductases genetics, Oxidoreductases metabolism, Point Mutation, Polymorphism, Genetic, Racial Groups genetics, Cytochrome P-450 Enzyme System genetics, Lung Neoplasms enzymology, Lung Neoplasms genetics
- Abstract
The cytochromes P450 participate in the metabolic activation of precarcinogens. Recent results reveal that many P450 genes are polymorphically distributed. Different investigators have tried to link polymorphic variants of the CYP1A1, CYP2D6 and CYP2E1 genes to the incidence of cancer, particularly lung cancer, in Asian and Caucasian populations. In the current overview we briefly summarize this research. It appears that interesting functionally linked interindividual differences in the CYP1A1 gene have been found and could be of importance in understanding differences in susceptibility to lung cancer. On the other hand, the data presented regarding CYP2D6 and CYP2E1 are less promising. We also describe interethnic differences in the P450 gene structures as a major obstacle for extrapolation of results between different ethnic groups.
- Published
- 1992
- Full Text
- View/download PDF
19. A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio.
- Author
-
Tybring G and Bertilsson L
- Subjects
- Cytochrome P-450 CYP2C19, Humans, Hydroxylation, Mephenytoin chemistry, Mephenytoin urine, Phenotype, Stereoisomerism, Aryl Hydrocarbon Hydroxylases, Cytochrome P-450 Enzyme System genetics, Cytochrome P-450 Enzyme System metabolism, Mephenytoin metabolism, Mixed Function Oxygenases genetics, Mixed Function Oxygenases metabolism
- Abstract
After a single oral dose of racemic mephenytoin the S/R ratio in urine can be used to phenotype extensive (EM) and poor metabolizers (PM) of S-mephenytoin. We confirmed the increased S/R ratio by storage time in EM because of the hydrolysis of a conjugate of S-mephenytoin excreted in EM, but not in PM. The S/R ratio in the 0-8 h urine increased 8- to 127-fold (from 0.22 +/- 0.16 to 9.9 +/- 11.3) after acid treatment of urine from 30 EM, but there was no effect of acid in that of 12 PM. We suggest that the phenotype of mephenytoin in combination with debrisoquine can be determined in the 0-8 h urine by estimating the mephenytoin S/R ratio before and after acid treatment.
- Published
- 1992
- Full Text
- View/download PDF
20. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects.
- Author
-
Andersson T, Regårdh CG, Lou YC, Zhang Y, Dahl ML, and Bertilsson L
- Subjects
- Adult, Female, Half-Life, Humans, Hydroxylation, Male, Middle Aged, Omeprazole administration & dosage, Omeprazole blood, Polymorphism, Genetic, Asian People genetics, Mephenytoin metabolism, Omeprazole metabolism, White People genetics
- Abstract
Twelve Caucasian healthy men and women, of whom six were poor metabolizers (PMs) and six were extensive metabolizers (EMs) of S-mephenytoin, together with 13 Chinese healthy men and women (five PMs and eight EMs), received a single oral 20 mg dose of omeprazole. Plasma levels of omeprazole and its two main metabolites, omeprazole sulphone and hydroxyomeprazole, were determined by HPLC. The mean (+/- SD) area under the plasma concentration-time curve (AUC) for omeprazole was 11.1 +/- 2.6 and 0.9 +/- 0.4 microM h in the Caucasian PMs and EMs, respectively. Corresponding values for elimination half-life were 2.3 +/- 0.4 and 0.7 +/- 0.4 h. In the Chinese PMs and EMs the AUC of omeprazole as 13.3 +/- 5.6 and 2.6 +/- 1.8 microM h. The AUCs of omeprazole were significantly higher in the Chinese EMs than in the Caucasian EMs possibly due to the higher proportion of heterozygotes in the former than in the latter group. The elimination half-life in the Chinese PMs and EMs was 2.4 +/- 0.2 and 0.8 +/- 0.2 h--similar to the observations in the Caucasian subjects. The maximum plasma concentration of hydroxyomeprazole was five-fold and four-fold higher in EMs compared to PMs among Caucasians and Chinese, respectively. The elimination half-life of the hydroxy metabolite was also longer in PMs than in EMs in both populations. The ratio between AUC for omeprazole and AUC for hydroxyomeprazole was 11.9 +/- 2.1 and 0.6 +/- 0.1 in Caucasian PMs and EMs, respectively. Corresponding values in the Chinese were 13.1 +/- 2.9 and 1.6 +/- 0.5.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.